Eventual Discovery in Humans of Antiviral Efficacy
Ok, very likely the SARS-CoV-2 virus, by natural selection, will devolve to a persisting pathogen, in the manner of colds and flues. No evidence whatsoever that any of the current "vaccines" will be able to extinguish the virus from any human population.
So, in two or three years from now, when blarcamesine is the SOC (standard of care) therapy for at least three morbidities, Rett syndrome, Parkinson's disease dementia, and Alzheimer's, it may be inadvertently discovered that those taking the drug don't suffer from SARS-CoV-2 infections themselves, or even other common viruses such as those of influenza and common colds.
First, is there any chance for this to be the case? Well, if activation by blarcamesine of the sigma-1 receptor protein facilitates (as it does) a diversity of "downstream" cellular maintenance functions, restored, optimized autophagy within cells will facilitate the destruction or expulsion of virions, virus particles. If viruses can't get inside cells, they can't replicate. They are a pathogenic dead end; merely an extraneous packet of non-functioning genetic nucleotides (DNA or RNA).
As Dr. Missling's long-ago statement "like an iceberg" might indicate, when tangentially in reference to the potentials of the Anavex sigma-1 receptor agonists, I'm certain that Anavex insiders know far more about their drugs than they are presently telling. It's not at all expensive or difficult to infect various common lab test animals (murines, rats and mice; Ceanorhabitis elegans, a common lab roundworm used for genetics, aging, and pathogen research) and see how treatments with Anavex molecules affect various microbial infections.
Restoration of optimized cell functions by blarcamesine might well yield profound antimicrobial outcomes. Not just time, but the reduced incidences of viral infections in people taking blarcamesine will tell.
Of course, categorically that fits inside the blarcamesine prophylaxis thesis; that dosing with blarcamesine will prevent the onset of various diseases, such as the targeted CNS diseases, along with the debilities of normal advanced aging.
Right now, we're still in the early chapters of the eventually gigantic Anavex story book. It won't be just Rett syndrome....
